I actually bought at 4.12 during those few days price was still lower, then had hopes that the rally would continue, but it has been cut short sadly. Perhaps it is time for me to exit my remaining shares as well...
Not an induce to buy or sell. Just the way I look at the current situation. Your own money you decide.
My top priority has always been safety first (capital preservation). Lose small money via cutloss Im still ok with it but I hate to lose bigger sum of money.
@AngTayKor I rather it being delayed than fail. UK gov is notorious for it's snail pace at getting things working/moving, especially coming to Christmas period!
Hello ElGato my Taurx kaki long time no see hahaha.... Thats why I said earlier "tu and tu is still better than Tankuku". Tankuku = fly kite string break liow 😥 Nevermind wait for CNY angpow tolong mai tu liow please 🙏
Have you read this article? I see liow sibei sian even before our FDA approval date. Really need an American big pharma TaiKor (with FDA connections + lobby groups like Alzheimers Association + KOLs) to JV the USA market la. Its corrupted and rigged!
Conflicts of interest FDA’s approval of donanemab comes after its contentious approval of aducanumab (Biogen and Eisai’s Aduhelm), despite a unanimous vote against it by the agency’s advisory committee (with one abstention). The advisers, many of whom were independent academics, objected to the agency’s decision to allow the company to switch its endpoint to a surrogate (reduced amyloid) rather than the clinical endpoint, which was measured in its studies but had not shown a clear cut benefit. Three advisers quit in protest, and a firestorm ensued in the press. A Congressional investigation followed, finding the FDA’s approval process to be “rife with irregularities.”
The second drug in the class, lecanemab (Eisai and Biogen’s Leqembi), came up for review in 2023. By then the FDA had replaced all 11 members of its advisory committee who had been critical of aducanumab. The agency appointed four new physicians to the committee to review lecanemab; all of them, or their employers, had had financial ties from 2017 through to the end of 2023 to the manufacturers of lecanemab. No public data on financial ties were available for two additional advisers, a biostatistician and patient representative.
The new and much smaller six member committee approved lecanemab unanimously, and the FDA gave its nod to the drug in July 2023.
When donanemab came up for review earlier this year, the FDA expanded its advisory committee to 11 members, including eight physicians. Using the public database OpenPayments, members’ CVs, disclosures in published articles, and the Google patent ownership database, The BMJ found that individual advisers received up to $62 000 (£47 000; €56 000) for consulting and speaking fees and up to $10.5m in research grants from 2017 through to the end of 2023 (table 1).
FDA pledges to take next steps on advisory committee changes
As the potential end of Robert Califf's time as FDA commissioner nears, he and a key deputy are continuing to push forward with changes to the advisory committee process.
In a Nature commentary published Monday, Califf and Deputy Commissioner Namandjé Bumpus shared their thinking about how the committee process might change. That includes potentially moving away from voting in many scenarios and relying more on committee discussions.
"Voting is not a mandatory part of meetings, and votes are typically not taken at meetings discussing general issues, such as clinical trial design or the development of guidance documents," Califf, Bumpus and Emily Helms Williams, regulatory counsel in the Office of Regulatory Counsel, Center for Drug Evaluation and Research, wrote in the commentary. "FDA staff may be primarily interested in the discussions and interpretation of particular aspects of the data rather than in a summative conclusion regarding risks and benefits." -------------
KNN another scheme to sideline AdComm to further consolidate powers within the FDA for easier corruption. I can bet money that Rob Califf's next job after leaving FDA will be Eli Lilly's Board of Director, just like the preceding FDA Commissioner Scott Gottlieb joining Pfizer Board.
US discusses possible Israeli strikes on Iran oil sites as Israel presses Lebanon campaign By Timour Azhari & Ari Rabinovitch / Reuters 04 Oct 2024, 07:50 am
War won't rattle here. War rattles mkts. GB up or down ?
Absolute, wild turbulence if Trump wins as he's going all-out to tariff and tax all imports. 60% on all China imports. 20% on all imports including fr S.E.Asia. No escape, no exceptions, no exit. All countries affected. All stk mkts affected.
Ms Alamak Kamala may win. But jialat also. Corporate tax to be increased by 33%. Soviet era price control on essential goods will surely lead to lack of production/supply + thriving black market.
Posted by MoneyMakers > | Report Abuse Dont trust GB longterm with such terrible QR Strong MYR not good for SG/US biz..rate cut savings also wont see in coming Q3 QR --------- Just matter of time break under 4.10 - might take few days (slow week) --------- Walao touch 4.10 again - looking good ------------ Only want see divergence under 4.10 by Friday kikiki ------------ Bearish closing 4.12 - gonna challenge 4.10 again nxt week
======================== PRICE IMMEDIATELY ROCKET TO 4.31 ========================
Aiya MM ah, no need to come here and act like you got real TA skill la. Last week too scared to show TA. Price rallied liow for 2 days liow also muted mule. Wed after price collapsed down liow then gave hindsight TA. MM sold before the big rally, the one and only Tin Kosong here. WAHAHAHA..... 🤣🤣🤣
Posted by MoneyMakers > 1 hour ago | Report Abuse AngTKlown overexcited Monday/Tuesday Expert no need say much - just let market prove AngTKlown ‘empty tin milo’ kikiki --------------
Last week Tin Kosong MM non-stop barking sell at 4.10 zone but trader bought cheap enjoyed the ride up. Savvy trader's milo tin inside got some profit la, all in a week's work. KNN kena sabo by Iran's missile attack, evaporated away a chunk of paper profit. After Iran's missile attack, safer to adopt "sell on rebound" strategy. Meagre profit but trader is appreciative. Thank You Genting 🙏
01/10/2024 Realised P&L for GENTING (GEN.MY) 49,000.00 02/10/2024 Realised P&L for GENTING (GEN.MY) 20,100.00 03/10/2024 Realised P&L for GENTING (GEN.MY) 11,150.00 04/10/2024 Closed Positions (Intraday) GENTING (GEN.MY) Sub-Total Profit/(Loss): 4,200.00
01/10/2024 Realised P&L for GENTING (GEN.MY) 49,000.00 02/10/2024 Realised P&L for GENTING (GEN.MY) 20,100.00 03/10/2024 Realised P&L for GENTING (GEN.MY) 11,150.00 04/10/2024 Closed Positions (Intraday) GENTING (GEN.MY) Sub-Total Profit/(Loss): 4,200.00 ------------------------------------------- Solid profits made over the past few days @Sifu ATK. Good job trading this short rally this week.
Thankfully, I also managed to make some small profits for myself this week. Would have made more but it was short-lived. At least we still made profit😀 Small wins are always better than big losses.
Posted by MoneyMakers > | Report Abuse Dont trust GB longterm with such terrible QR Strong MYR not good for SG/US biz..rate cut savings also wont see in coming Q3 QR --------- Just matter of time break under 4.10 - might take few days (slow week) --------- Walao touch 4.10 again - looking good ------------ Only want see divergence under 4.10 by Friday kikiki ------------ Bearish closing 4.12 - gonna challenge 4.10 again nxt week ======================== PRICE IMMEDIATELY ROCKET TO 4.31 ========================
Posted by MoneyMakers > 12 minutes ago | Report Abuse Aiyoyo AngTKlown I nvr say ‘sell’ 4.10 - I only share perfect TA (nvr care others buy/sell/hodl) Empty tin milo nonstop BS fake story other people aiyoyo P/s: mybe my fault prove u wrong too many times - nothing else can do except BS kikiki --------
Tin Kosong MM no need to spin BS check your own records here la.
"Just matter of time break under 4.10 - might take few days (slow week)".... Immediately gave your TA, immediately price rocket to 4.31. Your perfect TA ah? Hahahaha!!!!!!!!!!!!!!
MM ah you are biggest clown here la. Or you dont know how to spell the word S-H-A-M-E thats why you are always so shameless??? MM kena bad karma sold off just before the big rally now eating sour grapes jealous skillful trader made some profit. Aiya small profit only la. MM ah, go and learn real TA skills instead of eating sour grapes here la
@DonC, traders like to trade on real trends. Very pissed with myself for getting into this Genting trade last week wasted a lot of other much bigger opportunities. My stock trading sifu and kakis were buying big into HSI stocks recently all making very good money. After Iran missile attack, I was pre-occupied with "sell at rebound" strategy to lighten my Genting position. Should have immediately dump all and whacked oil related counters all up big this week. Wasted 2 big opportunities recently trading this weak pump and dump stock.
Stay healthy. As long as you are healthy, you still have time to recover and make a lot of money. Learn from mistake. Never too late. We still have TauRX. Waiting for Christmas gifts or Chinese new year Ang Pow.
Aiya @MC no need to post then delete these inconsequential publicly known news la. Next week when fear mongers come in here to 踢馆, @MC better dont hide below women's skirt again. Just f.ark n roar back at them like a real perma bull la. Cannot always depend on a "Non-Genting Investor" to fend off these fear mongers.
Share price is now caught between rocks and hard place.
Multiple tens of millions shares were bought cheap at 4.11 and 4.12 from 11/9 to 27/9 (including trader here). The rally has stalled, price reversed back down together with KLCI. These group of low priced buyers may choose to cut-win with minor profits. Any rally higher will be a good bonus.
Likewise, multiple tens of millions shares were also bought at 4.30 zone during 5/8 to 3/9, after 6 sen exdiv price will be 4.24 zone. These group of buyers were trapped at higher price with some waiting for better price to cut loss. Any rally will attract some from these group to cut loss.
Tough spot now. Savvy traders will lighten trading positions, safety always comes first. Anything can happen in the stock market. -------------------
@neohts, price trading at tight range for now. KLCI has been drifting down, foreigners have been big sellers recently at Bursa (-rm322m on 04/10/2024), probably to lock in profit and switching out of ringgit which has been depreciating over the past week. Traders tend to adopt "sell at rebound" strategy under such scenario.
I am surprised how the markets have been discounting the geopolitical risk. But the reality is that tensions continue to escalate in both the Middle East and the Russian-Ukraine conflicts. I think at some point of time the market will be alarmed.
"4.16 closing - reverse Monday qtr end rebalancing/windowdressing Lets see Friday how low can go" ------------
Aiya more likely Mad Mule wrong TA again la. Trader planning to use meagre profit for family Christmas Japan ski holiday sponsored by Genting. Thank You Genting.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
DonCandleone
72 posts
Posted by DonCandleone > 2 months ago | Report Abuse
Thanks for the advice ATK.
I actually bought at 4.12 during those few days price was still lower, then had hopes that the rally would continue, but it has been cut short sadly. Perhaps it is time for me to exit my remaining shares as well...